David Dinuoscio, MD
Pulmonary Disease · Hamilton, OHNPI 1528357571
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $75,092 of the $90,991 with a category attached, or 82.5%. Sanofi accounts for 75.8% of it on its own, with 35 other manufacturers making up the rest. 2025 is the largest year on record at $81,329, more than ten times the $481 reported in 2019. Among pulmonary disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 508 payments — averaging $179.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$69K
- Regeneron Healthcare Solutions, Inc.$13K
- AstraZeneca$3K
- GSK$1K
- Grifols USA, LLC$626
- Boehringer Ingelheim$529
- plus $3K from 30 others
What the payments were for
- Consulting fees$1,8832%
- Speaking & faculty fees$75,09283%
- Travel & lodging$2,2823%
- Food & beverage$11,44513%
- Education$2880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 60 | $68,954 |
| Regeneron Healthcare Solutions, Inc. | 65 | $13,079 |
| AstraZeneca | 87 | $3,052 |
| GSK | 85 | $1,447 |
| Grifols USA, LLC | 31 | $626 |
| Boehringer Ingelheim | 28 | $529 |
| Inogen, Inc. | 24 | $428 |
| Amgen | 9 | $405 |
| Mylan Specialty L.p. | 14 | $345 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $284 |
| Insmed, Inc. | 15 | $246 |
| Actelion Pharmaceuticals US, Inc. | 12 | $216 |
| Sunovion Pharmaceuticals Inc. | 7 | $179 |
| Pulmonx Corporation | 5 | $155 |
| Noah Medical Corporation | 1 | $134 |
| Genentech USA, Inc. | 5 | $123 |
| Electromed, Inc. | 13 | $116 |
| Viatris Specialty LLC | 5 | $112 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Philips North America LLC | 4 | $62 |
| Baxter Healthcare | 2 | $55 |
| Merck | 2 | $51 |
| Verona Pharma, Inc. | 2 | $36 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
| Jazz Pharmaceuticals Inc. | 1 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $26 |
| Covis Pharma GmbH | 1 | $23 |
| Vifor Pharma, Inc. | 1 | $22 |
| Harmony Biosciences LLC | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Mayne Pharma Commercial LLC | 1 | $20 |
| Novartis | 1 | $16 |
| United Therapeutics Corporation | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Circassia Inc. | 1 | $13 |
| 3b Medical, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$90,991 in reported general payments places this provider in the 95th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 250 | $204,053 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 167 | $133,536 |
| Dupixent PenDupilumab | 19 | $81,049 |
| Spiriva RespimatTiotropium Bromide | 55 | $39,403 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 52 | $37,686 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 57 | $30,046 |
| Spiriva HandihalerTiotropium Bromide | 25 | $22,863 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $19,977 |
| Incruse ElliptaUmeclidinium Bromide | 23 | $10,656 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 377 | $10,192 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $9,914 |
| DuleraMometasone/Formoterol | 24 | $8,966 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $6,431 |
| Tiotropium Bromide | 11 | $4,560 |
| Roflumilast | 43 | $3,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,447 | $264,732369 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,052 | $139,968188 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $529 | $77,089107 claims |
| MerckDulera | $51 | $8,96624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Hamilton
- Richard SternbergHamilton$33K
- Joseph KhabbazaAkron$655K
- Robert BaughmanCincinnati$640K
- Kristin HighlandCleveland$551K
- Bruce CorserCincinnati$502K
- Jason StieneckerLima$397K
- Mohammad SheattCincinnati$389K
- Mohammad KhanAkron$388K
- Thomas YungerDayton$353K
- Joseph CiceniaCleveland$350K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.